Surety Medicine 
Biological research may include potential accidental exposure to Francisella tularensis, which can cause Tularemia lesions. 

Biological surety programs may involve research into diseases such as Tularemia, 
which can cause a range of medical effects, including gland swelling and skin
ulcers such as the hand lesion shown above.
                                                                                                   - CDC photo

February 2016 Surety Medicine Teleconference:

DIAGNOSIS, EVALUATION AND TREATMENT
of LABORATORY-ACQUIRED TULAREMIA

WEDNESDAY, 17 February 2016 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time.  The topic for February will be Diagnosis, Evaluation and Treatment of Laboratory-Acquired Tularemia.  The presenter will be a physician who has served as Chief of the Special Immunizations Program at a biological research institute.

To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:

usarmy.apg.medcom-phc.mbx.surety-medicine@mail.mil

(NOTE:  The previously scheduled presentation, "CMA Interfaces with ASAP, FAP and EAP - Valuable Adjuncts to the PRP" will now occur Wednesday, 18 May 2016.)

ALERT:  FDA Simplifies Rule for Anthrax PEP

FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS

The US Food and Drug Administration (FDA) November 25, 2015 approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax.  The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.

Additional information is available from the FDA at: 

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm  


ALERT:  Autoinjector Shelf Life Extension Program:  Current Information

NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates. 
The latest approval extends 26 specific lot numbers of autoinjectors, some up to 31 October 2019.

Information on this page also includes the latest updates on shelf life extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and pralidoxime chloride auto-injectors manufactured by Meridian Medical Technologies.  Complete FDA information related to the auto-injector shelf life extension program can be found at: 

http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .  

__________________________________________________________________

SURETY MEDICINE TELECONFERENCE SCHEDULE FOR FY16 
                              All teleconferences begin at 1p.m. ET (US)

TOPIC                                                                                  Date              

Common Musculoskeletal Disorders, Treatments, and PRP Impacts

3/16/2016

 

The Indications for and Conduct of Hearing in Noise Testing for PRP Enrollees

4/20/2016

 

CMA Interfaces with ASAP, FAP and EAP:  Valuable Adjuncts to the PRP

5/18/2016

 

Traumatic Brain Injuries and the PRP:  Evaluation and Disposition 

6/15/2016

 

Case Studies in PRP Management

7/20/2016

 

Urinary Metabolites, Protein Adducts, and Bio-markers of Nerve and Vesicant Agent Exposure

8/17/2016

 

Endocrine Disorders and the PRP

9/21/2016

 

_______________________________________________________________

SURETY MEDICINE REGULATIONS, GUIDANCE and USEFUL LINKS:         
(Common Access Card or Army Knowledge Online account required for access to some documents)

AR 50-1 Biological Surety: http://armypubs.army.mil/epubs/pdf/r50_1.pdf 

AR 50-5 Nuclear Surety: http://armypubs.army.mil/epubs/pdf/r50_5.pdf 

AR 50-6 Chemical Surety: http://armypubs.army.mil/epubs/pdf/r50_6.pdf 

AR 50-7 Army Reactor Program: http://armypubs.army.mil/epubs/pdf/r50_7.pdf 

DA PAM 50-5 Nuclear Accident or Incident Response and Assistance Operations: http://armypubs.army.mil/epubs/pdf/p50_5.pdf 

DA PAM 385-61 Toxic Chemical Agent Safety Standards:  http://armypubs.army.mil/epubs/pdf/p385_61.pdf

Army Directive 2013-03 (Chemical Accident or Incident Response and Assistance): http://www.apd.army.mil/pdffiles/ad2013_03.pdf

TB MED 507 Heat Stress Control and Heat Casualty Management: http://armypubs.army.mil/med/DR_pubs/dr_a/pdf/tbmed507.pdf

TB MED 590 Red Blood Cell Testing and Quality Assurance:
http://armypubs.army.mil/med/DR_pubs/dr_a/pdf/tbmed590.pdf

Medical Command (MEDCOM) Regulation 40-55 Guidance on Occupational Health Practices for the Evaluation and Control of Occupational Exposures to Biological Select Agents and Toxins: https://www.us.army.mil/suite/doc/22064586

Additional Guidance Document Sources:

Army Publishing Directorate:  http://armypubs.army.mil/index.html